Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: Effects on perioperative bleeding and allogeneic transfusions  by Casati, Valter et al.
P erioperative hemorrhagic syndromes frequentlycomplicate the outcome of patients undergoing car-
diac surgery with cardiopulmonary bypass (CPB).1 The
interaction between the blood and foreign surfaces of
the extracorporeal circuit induces platelet dysfunction
and increased fibrinolytic activity, identified in previous
studies as the most important factors of postoperative
hemostatic derangement.2 The exposure to allogeneic
blood-derived products is related to the risk of non-
hemolytic transfusional and anaphylactic reactions, as
well as to infectious diseases such as acquired immuno-
deficiency syndrome and viral hepatitis.3 Procedures
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Objective: Since excessive fibrinolysis during cardiac surgery is frequently
associated with abnormal perioperative bleeding, many authors have advo-
cated prophylactic use of antifibrinolytic drugs to prevent hemorrhagic dis-
orders. We compared the effects of tranexamic acid (a synthetic antifibri-
nolytic drug) with aprotinin (a natural derivative product with
antifibrinolytic properties) on perioperative bleeding and the need for allo-
geneic transfusions. 
Methods: In a single-center prospective randomized unblinded trial, 1040
consecutive patients undergoing primary, elective cardiac operations with
cardiopulmonary bypass received either high-dose aprotinin or tranexamic
acid. The aprotinin group (518 patients) received 280 mg in 20 minutes
before the skin incision, 280 mg in the priming solution of the extracorpore-
al circuit, and a continuous infusion of 70 mg/h throughout the operation.
The tranexamic acid group (522 patients) received 1 g in 20 minutes before
the skin incision, 500 mg in the priming solution of the extracorporeal cir-
cuit, and a continuous infusion of 400 mg/h during the operation.
Postoperative bleeding, perioperative transfusions, and hematologic vari-
ables were evaluated at fixed times. Postoperative thrombotic complications,
intubation time, intensive care unit stay, and hospital stay were recorded. 
Results: Postoperative bleeding was similar in the 2 groups: aprotinin 250
mL (150-400 mL) versus tranexamic acid 300 mL (200-450 mL) (median
and 25th-75th quartiles), median difference of 50 mL (95% confidence inter-
vals, 0-50 mL). The number of transfusions and the outcome did not differ.
Conclusions: Tranexamic acid and aprotinin show similar clinical effects on
bleeding and allogeneic transfusion in patients undergoing primary elective
heart operations. Since tranexamic acid is about 100 times cheaper than
aprotinin, its use is preferable in this type of patient. (J Thorac Cardiovasc
Surg 2000;120:520-7)
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such as autologous blood predonation, intraoperative
isovolumic hemodilution, and equipment for blood cell
processing were introduced in cardiac surgery to
reduce the need for allogeneic transfusions.4 More
recently, the hemostatic effects of drugs such as apro-
tinin, tranexamic acid, ε-aminocaproic acid, desmo-
pressin, and dipyridamole have been studied. Whereas
the efficacy of desmopressin and dipyridamole could
not be demonstrated, aprotinin, a natural antiprotease
with antifibrinolytic properties, and ε-aminocaproic
acid and tranexamic acid, 2 synthetic antifibrinolytic
drugs, allowed a significant reduction of perioperative
bleeding and of the need for allogeneic transfusions.5
The disadvantages of aprotinin are the high cost and the
risk of anaphylactic reactions.6 To overcome these lim-
its, we decided to compare the hemostatic effects of
aprotinin with those of tranexamic acid, a synthetic,
low-cost antifibrinolytic drug 10 times more potent
than ε-aminocaproic acid, in a large series of adult
patients undergoing primary elective cardiac surgery.
The amount of the bleeding at various times was con-
sidered to be the main end point of the study; the enti-
ty of allogeneic blood-derived products transfused,
postoperative thrombotic complications, and outcome
were also considered.
Methods
Patient population and eligibility criteria. After obtain-
ing institutional review board and informed consent, from
June 1, 1996, to July 30, 1997, we conducted an unblinded
prospective study in 1040 consecutive adult patients (age >
18 years) scheduled for primary elective cardiac surgery
necessitating CPB in our institution. Exclusion criteria were
impaired renal function (serum creatinine level > 2 mg/dL),
advanced hepatic dysfunction (active chronic hepatitis or cir-
rhosis), and hematologic diseases. Preoperative treatment
with aspirin or heparin was not a contraindication to enroll-
ment in the study.
Treatment groups and operative procedures. By means
of a computer-generated random number sequence, 518
patients were randomly allocated to receive aprotinin, 280
mg for 20 minutes before the surgical incision, followed by a
constant infusion of 70 mg/h until the end of the operation,
while 280 mg was added to the priming solution of the CPB
circuit; 522 patients were randomized to receive tranexamic
acid, 1 g over 20 minutes before the surgical incision, fol-
lowed by a constant infusion of 400 mg/h during the entire
operative period, while 500 mg was added to the priming
solution of the CPB circuit. 
The anesthetic technique was standardized: each patient
was premedicated with intramuscular scopolamine (0.5 mg),
intramuscular morphine (0.1 mg/kg), and oral diazepam (0.1
mg/kg). Anesthesia was induced with fentanyl (0.02 mg/kg)
and propofol (2 mg/kg) or midazolam (0.15 mg/kg) in patients
with reduced cardiac function, defined as left ventricular ejec-
tion fraction below 35%. Muscle relaxation was obtained with
pancuronium bromide (0.1 mg/kg). Anesthesia was main-
tained with fentanyl (up to 0.05 mg/kg), an infusion of propo-
fol (6-10 mg · kg–1 · h–1) or midazolam (0.1-0.2 mg · kg–1 · h–1)
in patients with a reduced left ventricular ejection fraction,
and isoflurane and pancuronium as needed. Patients with a
reduced left ventricular ejection fraction and patients with pre-
operative compromised clinical conditions were monitored
with a thermodilution catheter (Swan-Ganz; Baxter Health-
care Corp, Edwards Division, Santa Ana, Calif). 
All patients were operated on through a median sternotomy.
During coronary artery bypass grafting procedures, the left
internal thoracic artery was routinely harvested through a con-
ventional pleurotomy access. The right internal thoracic artery
or the saphenous veins (or both) were also isolated when
needed, according to the surgeon’s preference. Before aortic
cannulation, porcine mucous heparin (3 mg/kg) was injected,
and further heparin was administered to maintain a kaolin-
activated coagulation time above 480 seconds. A hollow-fiber
membrane oxygenator was used, and the priming solution of
Table I.  Baseline characteristics
Aprotinin group (N = 518) Tranexamic acid group (N = 522) P*
Age, y 62 ± 10 61 ± 10 .1
Sex, No. (%) 412 (79.5) 415 (79.5) .9
Height, cm 168 ± 11 169 ± 10 .3
Weight, kg 73 ± 12 72 ± 12 .3
Baseline ejection fraction, % 60 ± 9 59 ± 10 .1
Patients with baseline ejection fraction < 35%, No. (%) 41 (7.9) 39 (7.5) .7
Coexisting illness, No. (%)
Hypertension 153 (29.5) 162 (31) .6
Diabetes 76 (14.7) 78 (14.9) .9
Peripheral vascular disease 29 (5.6) 31 (5.9) .8
Preoperative aspirin, No. (%) 92 (17.8) 98 (18.8) .7
Preoperative heparin, No. (%) 88 (17) 87 (16.7) .9
*The t test or χ2 test was used as appropriate; no significant differences were noted between groups. Plus-minus values are means ± standard deviation.
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the circuit consisted of 1750 mL of a balanced crystalloid/col-
loid solution (Ringer lactate, 1350 mL; 18% mannitol, 250
mL; and plasma expander, 150 mL). Nonpulsatile blood flow
was obtained with a roller pump (2.0-2.4 L · min–1 · m–2).
Blood temperature was kept between 32°C and 35°C.
Myocardial protection during aortic crossclamping was
achieved with the Buckberg method of blood cardioplegia.
The total dose of heparin administered during CPB was
reversed with protamine sulfate (ratio 1:1). Intraoperative car-
diogenic shock refractory to maximal inotropic therapy and
intra-aortic balloon pumping was treated by means of delayed
sternal closure and, if needed, with a ventricular assist device.
After termination of CPB, the remaining cellular content of
the oxygenator and salvaged blood were concentrated with a
cell separator and reinfused. Pericardial, mediastinal, and
pleural drains were inserted before chest closure and continu-
ous low-grade suction was instituted. 
Postoperative evaluation. Postoperative blood loss
through the drainage tubes was recorded during the first 24
hours and was not reinfused. Drains were removed when
bleeding in the previous 4 hours was less than 100 mL.
Plasma concentrations of hemoglobin, hematocrit, and
platelets, prothrombin time, activated partial thromboplastin
time (aPTT), creatinine, creatine kinase (CK), and creatine
kinase myocardial band isoenzyme (CK-MB) were evaluated
at the following times: after the induction of anesthesia
(basal), at admission to the intensive care unit (ICU) (time 1),
after 4 hours (time 2), and at 6 AM on the first and second
postoperative days (time 3 and time 4). As markers of fibri-
nolysis, serologic values of fibrinogen and D-dimers were
tested in a subgroup of 100 consecutive patients (50 patients
for each group). 
Transfusion protocol and criteria for surgical re-explo-
ration for bleeding. Criteria for transfusion were standard-
ized and indicated as units of packed red blood cells, fresh
frozen plasma, and platelet concentrates. Criteria for transfu-
sion of packed red blood cells were as follows: hematocrit
value less than 18% and hemoglobin value less than 6 g/dL
during CPB; hematocrit value less than 24% and hemoglobin
value less than 8 g/dL accompanied by signs or symptoms of
hypovolemia after CPB and during the ICU stay. The criteri-
on for transfusion of fresh frozen plasma was a prothrombin
time greater than 1.5 (international normalized ratio) with
excessive bleeding, defined as greater than 200 mL/h for 2
consecutive hours. The criterion for transfusion of platelet
concentrates was a platelet count less than 50,000/mm3 with
excessive bleeding (>200 mL/h for 2 consecutive hours).
Surgical re-exploration was performed if bleeding in the first
2 hours was greater than 300 mL/h or if greater than 200
mL/h for 4 consecutive hours with normal coagulation para-
meters. Bleeding of more than 600 mL in the first 24 hours
was considered excessive postoperative bleeding. Cases of
perioperative myocardial infarction (electrocardiographic
new Q waves and CK-MB/CK ratio greater than 10%), post-
operative renal failure (creatinine content 2 times the basal
value or need for dialysis), thromboembolic complications,
and major neurologic dysfunction (transient ischemic attack,
ictus cerebri) were recorded. Intubation time, ICU stay, and
hospital stay were also considered.
Statistical analysis. The main end point of the study was
the amount of total bleeding. Sample size was calculated
according to the formula for equivalence trial. The 2 treat-
ments will be considered equivalent if the 95% 2-sided con-
fidence interval for the treatment difference of total bleeding
falls within the interval ± 50 mL, assuming a standard devia-
tion of 200 mL. Five hundred subjects for each group are nec-
essary to have a power of 0.95 to conclude that the 2 treat-
ments are equivalent, if they are, in fact, identical. We used
the Shapiro-Wilk statistic to test the normality of the distri-
bution of continuous variables. When possible, log transfor-
mation was used to normalize distributions, and geometric
means are presented. To compare baseline, operative, and
postoperative variables, we used the t test or Mann-Whitney
U test as appropriate. Continuous variables are presented as
means ± standard deviation or as median and 25th to 75th
quartiles as appropriate. The χ2 test or Fisher exact test was
used to compare categoric data. A 2-way mixed-design analy-
sis of variance for repeated measures was used (PROC GLM;
SAS Institute, Inc, Cary, NC) to investigate the effects of the
time, of the treatment, and of the interaction time · treatment
Table II. Baseline hematologic data
Variable Aprotinin group (N = 518) Tranexamic acid group (N = 522) P*
Activated clotting time, s 152 [138-171] 151 [136-168] .07
Hemoglobin, g/dL 13.8 ± 1.6 13.9 ± 1.5 .2
Hematocrit, % 39.9 ± 4.4 40.3 ± 4.0 .2
Platelet count, 103/mm3† 209 ± 55 210 ± 57 .9
Prothrombin time, INR 1.04 ± 0.21 1.03 ± 0.2 .4
aPTT, ratio 1.21 ± 0.46 1.18 ± 0.42 .3
Fibrinogen, mg/dL† 357 ± 67 332 ± 86 .3
D-dimer, µg/mL† 0.79 ± 0.7 0.7 ± 0.5 .2
Creatinine, mg/dL 0.9 [0.74-1.02] 0.88 [0.7-1.03] .6
CK, U/L 68 [49-98] 67 [50-98] .9
Blood samples for evaluation of plasmatic concentrations of fibrinogen and D-dimer obtained from 100 consecutive patients (50 patients for each group). aPTT,
Activated thromboplastin time; CK, creatine kinase; INR, international normalized ratio.
*The t test or Mann-Whitney U test was used as appropriate; no significant differences were noted between groups. Plus-minus values are mean ± standard deviation.
Non-normally distributed data are indicated as median and (in brackets) 25th to 75th percentiles.
†Log transformed: values are geometric means.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 120, Number 3
Casati et al 523
on the coagulation data. The median differences of the bleed-
ing between groups at different considered times are present-
ed. As in equivalence trials, the confidence intervals are more
informative than the conventional significance test.
Confidence intervals of the median difference are also pre-
sented to evaluate the range for the possible true difference
between the treatments. As many comparisons were per-
formed between the 2 groups, only a highly statistically sig-
nificant P value (<.01) was considered to reject the null
hypothesis of no differences between groups. Data were ana-
lyzed with SAS statistical software.
Results
Following the “intention to treat” rule, all 1040
patients enrolled in the study were included in the sta-
tistical analysis, and their baseline characteristics and
hematologic data are indicated in Tables I and II. There
were no differences for each considered variable
between the groups. Thirty-five patients (aprotinin
group, n = 17; tranexamic acid group, n = 18) who dif-
fered from the main body of patients were included in
the analysis (see appendix). Table III shows operative
data. Statistically significant differences were found in
terms of the number of distal anastomoses performed in
patients undergoing myocardial revascularization and
in terms of minimum temperature recorded during
CPB. The 2 groups had the same number of patients
requiring delayed sternal closure or a ventricular assist
device for weaning from CPB. Table IV shows signifi-
cant differences found among postoperative hemato-
logic and coagulation data. Particularly in the aprotinin
group, the hematocrit and hemoglobin values were
higher (P < .001) and the aPTT was longer (P < .001)
at each given time. All the coagulation values changed
with time (P < .001). The time · treatment effect differ-
ence was statistically significant for hemoglobin,
hematocrit, and aPTT (P < .001). Plasma levels of fi-
brinogen and D-dimers, which were evaluated in a sub-
group of 100 subjects, did not change with time (fi-
brinogen, P = .06; D-dimer, P = .3) and were not
different in the 2 groups (fibrinogen, P = .7; D-dimer,
P = .3). Postoperative bleeding at various considered
times is presented in Table V. The median differences
of bleeding between groups ranged from 0 mL in the
first 4 hours to 50 mL for total bleeding, and the 95%
confidence intervals did not exceed 50 mL. As shown
in Table VI, the amount of allogeneic blood-derived
products transfused did not differ. Outcome data are
displayed in Table VII. Three patients in each group
required surgical re-exploration for excessive bleeding
without evidence of a surgical bleeding site; 5 patients
of the aprotinin group and 7 patients of the tranexamic
acid group had a surgical source for bleeding at re-
exploration. The same number of patients in the 2
groups had excessive bleeding (>600 mL in the first 24
hours). The prevalence of postoperative complications
did not differ between the 2 groups. Finally, intubation
time, ICU and hospital stay, and the mortality in the 2
groups were similar. 
Table III. Operative data
Aprotinin group Tranexamic acid group
(N = 518) (N = 522) P*
CABG, No. (%) 388 (74.9) 390 (74.7) .9
Valvular surgery, No. (%) 62 (12) 70 (13.4) .6
ASD repair, No. (%) 7 (1.4) 7 (1.4) .99
Combined intervention, No. (%) 61 (11.8) 55 (10.5) .6
Thermodilution catheter, No. (%) 89 (17.2) 89 (17.1) .9
CPB time, min 121 [95-145] 117 [92-137] .07
ACC time, min 83 [67-106] 81 [64-99] .06
Closure time, min 60 [60-75] 60 [60-75] .5
Distal anastomoses, no. 2.7 ± 0.9 2.9 ± 0.8 .001
Total heparin dose, mg 260 [210-300] 250 [210-300] .5
Total protamine dose, mg 260 [210-300] 250 [210-300] .6
Minimum hematocrit during CPB, % 23 [21-27] 23 [20-26] .06
Minimum temperature during CPB, °C 32.2 ± 0.9 32.4 ± 1.1 .002
Intraoperative surgical complications requiring allogeneic transfusions, No. (%) 3 (0.6) 3 (0.6) .99
IABP, No. (%) 22 (4.2) 24 (4.6) .8
Delayed sternal closure for weaning from CPB, no. (%) 2 (0.4) 1 (0.2) .7
VAD for weaning from CPB, No. (%) 3 (0.6) 3 (0.6) .99
ACC, Aortic crossclamping; ASD, atrial septal defect; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; IABP, intra-aortic balloon pump; 
VAD, ventricular assist device. Closure time is considered from the end of administration of protamine until the end of the surgical procedures.
*The χ2 test, Fisher exact test, or Mann-Whitney U test was used as appropriate; significant differences for P < .01. Plus-minus values are mean ± standard devia-
tion. Non-normally distributed data are indicated as median and (in brackets) 25th to 75th percentiles.
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Discussion
This is the largest single-center prospective random-
ized trial comparing the hemostatic effects of aprotinin
and tranexamic acid in patients undergoing cardiac
surgery with CPB. Perioperative hemorrhagic disorders
due to extracorporeal circulation are a frequent compli-
cation in cardiac surgery: excessive postoperative
bleeding increases the need for allogeneic blood-
derived products, with the consequent risk of transfu-
sion-related complications, and requires surgical re-
exploration in about 2% to 6% of patients, with an
increased rate of morbidity and mortality.1 Different
factors are implicated in coagulation disorders: surgical
causes, heparin rebound, complement activation,
hyperfibrinolysis, and platelet dysfunction. Previous
studies demonstrated that platelet dysfunction and
excessive fibrinolysis are the most frequently involved
nonsurgical causes: the contact of the blood with the
surfaces of the extracorporeal circuit induces the acti-
vation of the coagulation pathways, of fibrinolysis, and
of platelets, with their aggregation mediated by the
receptors glycoprotein IIb-IIIa and their degranula-
tion.7 The increase of fibrinolytic activity is due to the
increased release of tissue-plasminogen activator from
vascular endothelium, which starts during skin incision
and continues during sternotomy and surgical tissue
manipulation. This causes a rapid rise in plasma con-
centration during the first minutes of CPB, followed by
the transformation of plasminogen into plasmin and the
production of fibrin degradation products. At the same
time, platelet aggregation is induced by the increased
levels of thrombin and mediated by the fibrinogen and
fibrinogen receptors glycoprotein IIb-IIIa, with secre-
tion of α-granules and microparticle production. The
result of these processes is frequently an altered peri-
operative hemostasis.8
Drugs like aprotinin and tranexamic acid were intro-
duced in cardiac surgery to block the formation of plas-
min, preserve platelet function, and reduce perioperative
hemorrhagic disorders and the consequent increased
need for allogeneic transfusions. Aprotinin is a natural
derivative product obtained from bovine lung with an
inhibitory effect on a wide series of serine proteases such
as plasmin, kallikrein, and trypsin. The inhibition of plas-
min produces the antifibrinolytic effects; the inactivation
of kallikrein inhibits the contact activation system with
inhibition of intrinsic coagulation pathway and the pro-
duction of fibrin.9 Platelet function defect during CPB is
due to the decrease of both platelet surface glycoprotein
Ib receptors (adhesive receptor for von Willebrand factor)
and glycoprotein IIb-IIIa receptors (aggregation receptor
for fibrinogen). Aprotinin provides a platelet protective
effect with the preservation of both these receptors.10 A
high-dose aprotinin regimen is presently indicated as the
Table V. Postoperative bleeding
Aprotinin (N = 518) Tranexamic acid (N = 522) Difference between groups
Median [25th-75th percentiles] Median [25th-75th percentiles] Median [95% CI of median]
Bleeding 0-4 hours, mL 100 [50-200] 150 [100-200] 0 [0-50]
Bleeding 4-24 hours, mL 150 [100-200] 150 [100-200] 0 [0-0]
Total bleeding, mL 250 [150-400] 300 [200-450] 50 [0-50]
CI, Confidence interval.
Table IV.  Postoperative coagulation data
Treatment Baseline Time 1 Time 2 Time 3 Time 4
Hemoglobin Aprotinin 13.8 ± 1.6 11.5 ± 1.7 11.5 ± 1.6 11.1 ± 1.4 10.7 ± 1.3
Tranexamic acid 13.9 ± 1.5 11.2 ± 1.5 11.1 ± 1.5 10.9 ± 1.4 10.3 ± 1.2
Hematocrit Aprotinin 39.9 ± 4.4 33.9 ± 4.8 33.9 ± 4.6 32.7 ± 4.1 31.4 ± 3.9
Tranexamic acid 40.3 ± 4.0 32.9 ± 4.6 32.8 ± 4.6 31.7 ± 4.0 30.2 ± 3.7
PLT count† Aprotinin 209 ± 55 132 ± 42 140 ± 42 136 ± 45 126 ± 43
Tranexamic acid 210 ± 57 130 ± 42 137 ± 48 135 ± 45 129 ± 43
Pt Aprotinin 1.04 ± 0.21 1.24 ± 0.17 1.18 ± 0.14 1.15 ± 0.11 1.1 ± 0.13
Tranexamic acid 1.03 ± 0.2 1.23 ± 0.21 1.17 ± 0.12 1.14 ± 0.14 1.1 ± 0.17
aPTT Aprotinin 1.21 ± 0.46 1.65 ± 0.38 1.44 ± 0.33 1.35 ± 0.23 1.29 ± 0.25
Tranexamic acid 1.18 ± 0.42 1.26 ± 0.22 1.19 ± 0.21 1.2 ± 0.17 1.22 ± 0.23
aPTT, Activated thromboplastin time; df, degrees of freedom; PLT, platelet count; Pt, prothrombin time.
*Two-way mixed-model analysis of variance for repeated measures.
†Log-transformed: values are geometric mean ± standard deviations.
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most effective; it is the most widely studied, and it is the
protocol used in our study. Introduced for the treatment of
high-risk patients (those having repeat operations, endo-
carditis, or preoperative aspirin), it has also proven effec-
tive in low-risk patients.11-14 Tranexamic acid is a syn-
thetic antifibrinolytic drug more recently introduced in
cardiac surgery. It acts by forming a reversible complex
with the plasminogen through the lysine binding sites for
fibrin. The saturation of these sites displaces the plas-
minogen from the fibrin surface, preventing the binding
of plasmin to fibrinogen or to fibrin monomers.15
When we started our studies on antifibrinolytic
drugs, few studies comparing high-dose aprotinin with
tranexamic acid had been performed. The results were
ambiguous and limited to small series of patients.16-20
Before starting this trial, we performed a pilot prospec-
tive randomized study in which 210 patients received
tranexamic acid, ε-aminocaproic acid, or aprotinin,
evaluating postoperative bleeding and the need for allo-
geneic transfusions. The results were that tranexamic
acid but not ε-aminocaproic acid showed effects simi-
lar to those of aprotinin.21 Therefore, to confirm these
initial results, we decided to compare aprotinin and
tranexamic acid in a large number of patients scheduled
for primary elective cardiac surgery. We did not con-
sider a control group necessary because we deemed
satisfactory the number of studies in the literature in
which the efficacy of the 2 drugs had been demonstrat-
ed when compared with a placebo.11-14,22,23
A discussion of our results must consider the differ-
ences between the 2 groups as shown by statistical analy-
sis. In line with previous reports, we found aPTTs to be
significantly longer in the aprotinin group. This differ-
ence is due to the inhibition of the bean phosphatide acti-
vator used in the whole blood aPTT assay induced by
aprotinin.24 The other differences are likely due to the
large size of the series we studied. The differences of
postoperative data (minimum temperature during CPB
and number of distal anastomoses performed) and post-
operative values of hematocrit and hemoglobin are very
small and without clinical significance; particularly in the
aprotinin group, the hematocrit and hemoglobin values
are only slightly higher at each point (eg, 1% and 0.4
g/dL, respectively, at time 4). The median of total blood
Table VI.  Perioperative allogeneic transfusions
Aprotinin group (N = 518) Tranexamic acid group (N = 522) P*
PRBC in OR, units (patients transfused) 238 (106) 219 (100) .6
PRBC 0-4 hours, units (patients transfused) 252 (108) 234 (100) .5
Total PRBC, units (patients transfused) 543 (185) 504 (178) .5
FFP in OR, units (patients transfused) 38  (9) 41 (8) .8
FFP 0-4 hours, units (patients transfused) 110 (25) 116 (25) .99
Total FFP, units (patients transfused) 169 (27) 181 (30) .7
PLTC in OR, units (patients transfused) 16 (2) 22  (3) .99
PLTC 0-4 hours, units (patients transfused) 42 (6) 22  (3) .3
Total PLTC, units (patients transfused) 64 (6) 46 (4) .3
Total number of patients transfused (%) 185 (36) 178 (34) .5
FFP, Fresh frozen plasma; OR, operating room; PLTC, platelet concentrate; PRBC, packed red blood cells.
*χ2 Test; no differences between groups.
Treatment effect Time effect Treatment* Time interaction
F(df) P* F(df) P* F(df) P*
7.7(1,771) .006 55.8(4.768) <.001 6.78(4,768) <.001
9.7(1,773) .002 72.1(4,770) <.001 6.07(4,770) <.001
.001(1,769) .96 74.6(4,766) <.001 1.76(4,766) .1
1.1(1,796) .3 19.4(4,793) <.001 0.16(4,793) .9
143(1,795) <.001 84.4(4,794) <.001 38.1(4,792) <.001
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loss is just 50 mL lower, with a confidence interval rang-
ing from 0 to 50 mL, the value we considered to be clin-
ically acceptable for equivalence between the 2 drugs.
Furthermore, we did not find differences in the number of
perioperative allogeneic transfusions, percentage of
patients receiving a transfusion, and prevalence of re-
exploration for bleeding. These results are similar to
those shown in a recent study.25
However, there are impressive differences regarding
the cost of the 2 drugs: for our institution the high-dose
aprotinin protocol costs an average of $370 per patient,
whereas the described tranexamic acid protocol costs
about $4 per patient. We annually perform about 1500
elective operations, and this results in a cost difference
of about $500,000. To reduce the cost of treatment with
aprotinin, various authors suggested the administration
of lower doses; 2 regimens have been principally stud-
ied: half-dose or pump-prime only dosage. The results
of these studies are not uniform, and the safety of these
pharmacologic protocols is questionable.26,27
Another limit related to the use of aprotinin is the prob-
ability of anaphylactic reactions. Recent studies have
shown the incidence of such reactions to be 1% to 2% for
the first exposure and 2% to 4% at re-exposure.6-28 This
is an important concern because of the progressive
increase in patients undergoing redo cardiac operations.
In our study, only 1 patient with no history of allergy or
previous administration of aprotinin had anaphylactic
shock at the start of the initial bolus, which required
emergency pharmacologic treatment and CPB support.
The analysis of postoperative complications does not
show any difference between the 2 groups and is in line
with the data reported in the literature. 
An important point about the safety of antifibrinolytic
therapy concerns the risk of thrombosis, particularly of
venous grafts. In our study, the 2 groups showed the same
low incidence of perioperative myocardial infarction
(about 2%). In a recent large multicenter study, 2928
grafts in 870 patients were analyzed by early angiogra-
phy. No significance difference was observed between
the 436 patients treated with aprotinin and the 434 treat-
ed with placebo in perioperative acute myocardial infarc-
tion and mortality; however, an increased probability of
early occlusion of venous grafts in vessels less than 1.5
mm in diameter or of poor quality (aprotinin group
15.4% vs control group 10.9%; P = .03) was seen in
patients treated with aprotinin.29 Incomplete revascular-
ization resulting from early graft occlusion may predis-
pose the patient to late myocardial infarction, recurrent
angina, and reduced event-free survival, suggesting cau-
tion regarding an indiscriminate use of aprotinin.30
Finally, in analyzing data about the intubation time,
ICU and hospital stays, and incidence of mortality, we
observed no differences between the groups, demon-
strating that the different treatment does not affect the
outcome.
Conclusions
Our study clearly demonstrates in a large population
undergoing primary elective cardiac surgery that
tranexamic acid is clinically as effective as high-dose
aprotinin in preventing perioperative bleeding and the
need for allogeneic transfusions. Because of the lower
costs and a lower risk of adverse reactions, we think
that tranexamic acid is preferable to aprotinin in this
type of patient. 
Table VII.  Postoperative outcomes and complications
Aprotinin group (N = 518) Tranexamic acid group (N = 522) P*
Intubation time, h 9 [7-11] 9 [7-11] .5
ICU stay, days 1 [1-2] 1 [1-2] .6
Hospital stay, days 9 [7-11] 9 [7-10] .09
Re-exploration for bleeding without surgical source, No. (%) 3 (0.6) 3 (0.6) .99
Re-exploration for surgical bleeding, No. (%) 5 (1) 7 (1.3) .8
Excessive blood loss, No. (%) 51 (9.8) 53 (10.1) .8
Perioperative AMI, No. (%) 9 (1.7) 11 (2.1) .7
Early reoperation for ischemia, No. (%) 3 (0.6) 3 (0.6) .99
Postoperative renal insufficiency:
Creatine twice the baseline, No. (%) 17 (3.3) 16 (3.1) .8
Postoperative dialysis, No. (%) 7 (1.4) 7 (1.3) .8
Pulmonary embolism, No. (%) 0 1 (0.2) .99
Major neurologic dysfunction, No. (%) 4 (0.8) 4 (0.8) .99
Death, No. (%) 12 (2.3) 10 (1.9) .6
AMI, Acute myocardial infarction; ICU, intensive care unit. Excessive bleeding is considered as greater than 600 mL in the first 24 hours.
*The χ2 test or Fisher exact test and Mann-Whitney U test were used as appropriate. Plus-minus values are mean ± standard deviation; non-normally distributed data
are indicated as median and (in brackets) 25th to 75th percentiles.
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Appendix
Reasons Aprotinin group (N = 518) Tranexamic acid group (N = 522)
Pharmacologic protocol error, No. (%) 0 1 (0.2)
Anaphylactic shock, No. (%) 1 (0.2) 0
Intraoperative surgical complications necessitating homologous transfusions, No. (%) 3 (0.6) 3 (0.6)
Delayed sternal closure for weaning from CPB, No. (%) 2 (0.4) 1 (0.2)
VAD for weaning from CPB, No. (%) 3 (0.6) 3 (0.6)
Re-exploration for surgical bleeding, No. (%) 5 (1) 7 (1.3)
Early reoperation for ischemia, No. (%) 3 (0.6) 3 (0.6)
Total number (%) 17 (3.4) 18 (3.5)
There were no significant differences between the 2 groups. CPB, Cardiopulmonary bypass; VAD, ventricular assist device.
